Concomitant anti-IL-10 treatment enhanced efficacy of cyclophosphamide and bone marrow-derived dendritic cell transfer therapy via limiting MDSC suppressive functions allowing enhanced NK cell anti-tumour effector function. The gene discussed is IL10; the disease is neoplasm.